News

Novo Nordisk's weight loss challenge in five charts
Booming sales of Wegovy powered the company to become Europe's most valuable, but it has lost over $400 billion in market ...
Novo Nordisk: The Market Has Lost Its Mind
Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...
Novo Nordisk, TSMC, Glencore: Stocks Around the World in Focus
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
Cash pay is 'going to constitute a major part of the Wegovy business': Novo Nordisk CFO
Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...
Why Novo Nordisk Stock Flew Higher on Friday
Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...
CNN2y
Novo Nordisk limits Wegovy doses for new patients as demand ... - CNN
Novo Nordisk, maker of the weight-loss drug Wegovy, said it would limit supply of starter doses as demand outpaces the company’s manufacturing capacity.
Wegovy, Mounjaro Sales in India Double on Month in July
Sales of Wegovy, launched locally in June, more than doubled to 5,000 units or 70 million rupees ($798,230) in July, the data ...
The Motley Fool1y
Surprise! Novo Nordisk's Wegovy Just Achieved Another Milestone. Here's ...
Although Ozempic is Novo Nordisk's current crown jewel, Wegovy is quickly becoming a force on its own. Earlier this year, investors learned that sales of Wegovy rose 393% year over year in ...